immune-related adverse events - Globe Thesis

Keyword [immune-related adverse events] Result: 1 - 18 \| Page: 1 of 1
1.	Toxicities And Management Of Immune Checkpoint Inhibitors In Cancer Immunotherapy
2.	Efficacy And Immune-related Adverse Events Induced By PD-1/PD-L1 And CTLA-4 Inhibitors In Advanced NSCLC
3.	Risk Of Immune-Related Adverse Events Associated With Ipilimumab-Plus-Nivolumab And Nivolumab Therapy In Cancer Patients
4.	Adverse Events Associated With Immune Checkpoint Inhibitors For Solid Tumor:A Systematic Review And Meta-analysis
5.	Incidence And Risk Of PD-1/PD-L1 Inhibitors Related Pneumonitis In Patients With Advanced Cancer
6.	Clinical Observation Of Immune Checkpoint Inhibitor In The Treatment Of Advanced Non-Small Cell Lung Cancer
7.	Correlation Between Immune Related Adverse Events With Clinical Efficacy In Solid Tumors Treated With Immune Checkpoint Inhibitors
8.	Biomarkers Associated With Response And Immune-related Adverse Events For Immune Checkpoint Inhibitors
9.	Multi-group Biomarker Exploration And Prediction Model Establishment Of Lung Cancer Immunotherapy-related Adverse Reactions
10.	A Meta-analysis Of The Efficacy And Safety Of Immune Checkpoint Inhibitors In The Treatment Of Tumor Patients With Autoimmune Diseases
11.	Immune-related Adverse Events Caused By PD-1/PD-L1 Inhibitor Therapy Predict Efficacy Of Patients With Advanced Cancer
12.	Analysis Of Characteristics,predictive Factors And Correlation With Survival Outcomes Of Immunotherapy-related Adverse Events
13.	Study On The Correlation Between The Clinical Characteristics Of Advanced Non-small Cell Lung Cancer And The Prognosis Of Immunotherapy
14.	Meta-analysis Of The Correlation Between Immune-related Adverse Events And Efficacy Of Immune Checkpoint Inhibitors In The Treatment Of Non-small Cell Lung Cancer
15.	Efficacy And Immune-Related Adverse Events Induced By PD-1/PD-L1 Inhibitors As First-Line Treatment For Advanced Non-Small Cell Lung Cancer:a Meta-Analysis Of Randomized Controlled Trials
16.	Correlation Between Immune-Related Adverse Events Of Immune Checkpoint Inhibitors And The Efficacy
17.	Clinical Observation Of PD-1 Inhibitor In The Treatment Of Advanced Non Small Cell Lung Cancer
18.	Predictive Value Of Immune Cell Levels For Immune-related Adverse Events In Patients With Advanced Non-small Cell Lung Cancer ��A Single-institution Retrospective Study
<<First <Prev Next> Last>> Jump to